trending Market Intelligence /marketintelligence/en/news-insights/trending/IQaRHkWxT8Q_aV5-dujWgQ2 content esgSubNav
In This List

Antares Pharma adds Cerecor CEO to board

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Antares Pharma adds Cerecor CEO to board

Antares Pharma Inc. said it appointed Cerecor Inc. Peter Greenleaf to its board.

Greenleaf also serves as chairman of BioDelivery Sciences International Inc.'s board, and is a director of Eyetech Pharmaceuticals. His previous roles include chairman and CEO of Sucampo Pharmaceuticals Inc., now owned by Mallinckrodt Public Ltd. Co., and president of MedImmune LLC and MedImmune Ventures Inc., the biologics arm and venture capital arm, respectively, of AstraZeneca PLC.

Ewing, N.J.-based Antares Pharma is a specialty pharmaceutical company that develops and sells self-administered parenteral pharmaceutical products and technologies worldwide.